ProfileGDS5678 / 1444668_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 23% 20% 20% 18% 18% 20% 23% 19% 19% 19% 20% 19% 24% 20% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5596823
GSM967853U87-EV human glioblastoma xenograft - Control 22.4674220
GSM967854U87-EV human glioblastoma xenograft - Control 32.4731320
GSM967855U87-EV human glioblastoma xenograft - Control 42.392318
GSM967856U87-EV human glioblastoma xenograft - Control 52.3951918
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5302520
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5668423
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4479219
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4298319
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.455619
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4690120
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4345619
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5626524
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4631920